ES2548435T3 - Reactivos y métodos para el tratamiento y la prevención del cáncer - Google Patents

Reactivos y métodos para el tratamiento y la prevención del cáncer Download PDF

Info

Publication number
ES2548435T3
ES2548435T3 ES07754097.9T ES07754097T ES2548435T3 ES 2548435 T3 ES2548435 T3 ES 2548435T3 ES 07754097 T ES07754097 T ES 07754097T ES 2548435 T3 ES2548435 T3 ES 2548435T3
Authority
ES
Spain
Prior art keywords
cells
cancer
tumor
cell
extracts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07754097.9T
Other languages
English (en)
Spanish (es)
Inventor
Kayvan R. Niazi
Shahrooz Rabizadeh
Dale E. Bredesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buck Institute for Research on Aging
Original Assignee
Buck Institute for Research on Aging
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Institute for Research on Aging filed Critical Buck Institute for Research on Aging
Application granted granted Critical
Publication of ES2548435T3 publication Critical patent/ES2548435T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES07754097.9T 2006-03-27 2007-03-27 Reactivos y métodos para el tratamiento y la prevención del cáncer Active ES2548435T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US389695 2006-03-27
US11/389,695 US9107863B2 (en) 2006-03-27 2006-03-27 Reagents and methods for cancer treatment and prevention
PCT/US2007/007526 WO2007126787A2 (en) 2006-03-27 2007-03-27 Reagents and methods for cancer treatment and prevention

Publications (1)

Publication Number Publication Date
ES2548435T3 true ES2548435T3 (es) 2015-10-16

Family

ID=38533710

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07754097.9T Active ES2548435T3 (es) 2006-03-27 2007-03-27 Reactivos y métodos para el tratamiento y la prevención del cáncer
ES15180408.5T Active ES2655909T3 (es) 2006-03-27 2007-03-27 Reactivos y métodos para el tratamiento y prevención del cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15180408.5T Active ES2655909T3 (es) 2006-03-27 2007-03-27 Reactivos y métodos para el tratamiento y prevención del cáncer

Country Status (8)

Country Link
US (4) US9107863B2 (cg-RX-API-DMAC10.html)
EP (2) EP2004219B1 (cg-RX-API-DMAC10.html)
JP (2) JP5422377B2 (cg-RX-API-DMAC10.html)
CN (1) CN101443036A (cg-RX-API-DMAC10.html)
AU (1) AU2007245169B2 (cg-RX-API-DMAC10.html)
CA (1) CA2647542A1 (cg-RX-API-DMAC10.html)
ES (2) ES2548435T3 (cg-RX-API-DMAC10.html)
WO (1) WO2007126787A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376495B2 (ja) 1992-08-18 2003-02-10 ソニー株式会社 接着剤の塗布方法及び接着治具
US9107863B2 (en) 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention
CZ300806B6 (cs) * 2007-07-18 2009-08-12 Ústav experimentální mediciny AV CR, v.v.i. Imunostimulacní úcinky trilobolidu a zpusob jeho prípravy
US9446141B2 (en) * 2013-03-15 2016-09-20 Genspera, Inc. Methods of producing cancer compounds
EP2796137A1 (en) * 2013-04-22 2014-10-29 Universität des Saarlandes SERCA inhibitor and Calmodulin antagonist combination
CN112891354B (zh) * 2021-03-18 2022-10-21 新乡医学院 MDM2抑制剂Nutlin-3a在制备激活内质网应激诱导的癌细胞凋亡药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
IN165717B (cg-RX-API-DMAC10.html) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
AU5458500A (en) 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
JP2001010973A (ja) * 1999-06-29 2001-01-16 Dnavec Research Inc がんワクチン
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US7056491B2 (en) * 2000-11-08 2006-06-06 Wisconsin Alumni Research Foundation Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
CA2356438A1 (en) * 2001-09-05 2003-03-05 Andre Pichette Use of terpenes and derivatives as potentiators of antitumor agents in the treatment of cancers
US7402406B2 (en) * 2001-10-31 2008-07-22 Astellas Pharma Inc. Methods of evaluating phosphatase inhibitors
WO2003087129A2 (en) * 2002-04-08 2003-10-23 Siga Technologies, Inc. Immunogenic peptides, and method of identifying same
US20060148064A1 (en) 2002-10-25 2006-07-06 Srivastava Pramod K Apparatus and method for immunotherapy of a cancer through controlled cell lysis
WO2005051423A2 (en) * 2003-11-30 2005-06-09 Yeda Research And Development Co. Ltd Methods and agents for immune modulation and methods for identifying immune modulators
US9107863B2 (en) * 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention

Also Published As

Publication number Publication date
US9885704B2 (en) 2018-02-06
US8895031B2 (en) 2014-11-25
EP2004219A4 (en) 2010-06-30
AU2007245169A1 (en) 2007-11-08
CA2647542A1 (en) 2007-11-08
WO2007126787A2 (en) 2007-11-08
US20100278874A1 (en) 2010-11-04
EP2974738A1 (en) 2016-01-20
CN101443036A (zh) 2009-05-27
US20070224207A1 (en) 2007-09-27
EP2004219A2 (en) 2008-12-24
EP2004219B1 (en) 2015-09-16
ES2655909T3 (es) 2018-02-22
JP5422377B2 (ja) 2014-02-19
US9107863B2 (en) 2015-08-18
WO2007126787A3 (en) 2008-10-23
AU2007245169B2 (en) 2012-05-24
EP2974738B1 (en) 2017-11-15
US20180128816A1 (en) 2018-05-10
JP5712257B2 (ja) 2015-05-07
US20160069864A1 (en) 2016-03-10
JP2014028815A (ja) 2014-02-13
JP2009535298A (ja) 2009-10-01

Similar Documents

Publication Publication Date Title
Showalter et al. Cytokines in immunogenic cell death: applications for cancer immunotherapy
Wang et al. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3–IRF3 signaling and type I interferons in dendritic cells
Son et al. Immunogenic cell death induced by ginsenoside Rg3: significance in dendritic cell-based anti-tumor immunotherapy
Le Naour et al. Trial watch: Toll-like receptor ligands in cancer therapy
US20180128816A1 (en) Reagents and Methods for Cancer Treatment and Prevention
Zhou et al. Single high-dose radiation enhances dendritic cell homing and T cell priming by promoting reactive oxygen species-induced cytoskeletal reorganization
KR20120055550A (ko) 암 치료용 화합물을 확인하는 방법
Luo et al. Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo
US12234480B2 (en) Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells
Hahn et al. Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors
EP4262821A1 (en) Therapeutic rna for treating cancer
Alam et al. A therapeutic vaccine in combination with cyclic GMP–AMP cures more differentiated melanomas in mice
Cho et al. Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model
HK40105290A (en) Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c)
HK40100442A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
KR20230101287A (ko) K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101284A (ko) K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101285A (ko) K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101286A (ko) K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20230101283A (ko) K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
Park et al. Effects of Cirsium japonicum var. ussuriense Extract on Tumor Immunity
Dickerson et al. Peptide Targeting of EphA2 in Epithelial Ovarian Cancer
Yamaoka et al. WS/PP-024b-11 Spatiotemporal regulation of heat shock protein 90-chaperoned self-DNA and CpG-oligodeoxynucleotide for type-I interferon induction via targeting to static early endosome Y. Tamura, K. Saito, K. Okuya, T. Torigoe, N. Sato. Sapporo Medical University School of Medicine, Sapporo, Japan
HK40023269B (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
HK1256917B (en) Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor